Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 63
- Registration Number
- NCT05312671
- Locations
- 🇺🇸
Johns Hopkins University: Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 452
- Registration Number
- NCT05302284
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 784
- Registration Number
- NCT05298423
- Locations
- 🇨🇳
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
🇨🇳Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
🇨🇳The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 295
- Registration Number
- NCT05294172
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 63
- Registration Number
- NCT05286619
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
- Conditions
- Distal Bile Duct AdenocarcinomaMetastatic Malignant Neoplasm in the PeritoneumStage IV Distal Bile Duct Cancer AJCC v8Stage IV Intrahepatic Bile Duct Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVB Gallbladder Cancer AJCC v8Intrahepatic CholangiocarcinomaGallbladder Carcinoma
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05285358
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 50
- Registration Number
- NCT05281406
- Locations
- 🇩🇪
Universitätsklinik Köln, Lung Cancer Group Cologne - Innere Medizin I, Köln, Germany
🇩🇪LMU-München Pneumologie und Thorakale Onkologie Medizinische Klinik V; Innenstadt, München, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik, Hamburg, Germany
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 128
- Registration Number
- NCT05281003
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 250
- Registration Number
- NCT05268614
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸UF Health Proton Therapy Institute, Jacksonville, Florida, United States
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT05261399
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.